Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
MOVE Peds
MOVE Peds
Sponsor study identifier
Secondary identifiers
observational
80
2 countries
7
Study Start
May 22, 2025
Actual (reported)Primary Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The primary goal of this study is to validate motor and functional outcomes and refine clinical trial strategies for pediatric-onset FSHD
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 23, 2025
Actual (reported)February 26, 2025
Actual (reported)May 22, 2025
Actual (reported)May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Pediatric FSHD-COM
Investigators will collect the FSH-Composite outcome measure for children and adolescents. This measure assesses multiple body regions identified as important by patients, including leg function, shoulder and arm function, trunk function, hand function, and functional balance. The FSHD-COM Peds has been modified to include lighter weights for shoulder abduction and flexion, as well as elbow flexion, to accommodate the motor development and lower strength levels seen in children. Although the FSHD-COM Peds involves different measurements for each body region, these measurements are combined to produce a single composite score. The total score for the FSHD-COM Peds is out of 84, representing one comprehensive outcome measure
Baseline-2 years
Reachable Work Space
Subjects are seated in front of a stereo-camera and perform a standardized upper extremity movement protocol under the supervision of a study clinical evaluator. Five-hundred-gram wrist weights will be added. The standardized simple set of movements consist of lifting the arm from the resting position to above the head while keeping the elbow extended, performing the same movement in vertical planes at around 0, 45, 90, 135 degrees. The second set of movements consists of horizontal sweeps at the level of the umbilicus and shoulder.
Baseline-2 years
Quantitative MRI (qMRI) Fat Fraction %
Baseline-2 years
Quantitative MRI (qMRI) Lean Muscle Volume (mL)
Baseline-2 years
Quantitative MRI (qMRI) Total Volume
Baseline-2 years
Quantitative MRI (qMRI) STIR+ ( %)
Baseline-2 years
PROMIS Pediatric physical activity questionnaire (8 questions)
Baseline-2 years
Neuro Qol Fatigue Scale
Baseline-2 years
The Facial Disability Index (FDI) physical score
Baseline-2 years
Cohort One will be individuals who are able to complete the 10 meter walk/run test in less than twelve seconds
cohort two will be individuals who complete the 10 meter walk/run test in more than 12 seconds or is no longer able to complete.
This study is meant to target children most likely to be included in clinical trials: children who are clinically affected, old enough to perform functional measures, and still ambulatory. On outcomes proposed for MOVE Peds they would have room to show progression or improvement and be at a stage ideal to assess potential inclusion criteria: in particular whether symptom onset age or genetics separate early-onset from other childhood onset FSHD, or whether they exist on a spectrum of severities. At least half will qualify as early-onset (facial weakness before age 5 and shoulder weakness before age 10 or symptom onset before age 18 and 1-3 D4Z4 repeats). We will be also looking at a small cohort of early onset participants who's ambulation has been affected or is no longer able to ambulate. this will help us assess all child progression and understand the connection of early-onset and ambulation
Stanford University
Palo Alto, California, 94304, United States
University of Iowa
Iowa City, Iowa, 52242, United States
DNA will be collected at baseline for genetic testing and will be sent to Leiden for assessment. DNA, plasma, and serum biomarker samples that are collected will be sent to Coriell which will be stored in a biorepository for future research.
Jeffrey Statland, MD
University of Kansas Medical Center
First Submitted
January 23, 2025
First Posted
February 26, 2025
Study Start
May 22, 2025
Actual (reported)Primary Completion
May 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation
Contact the study team to confirm eligibility.
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
University of Rochester
Rochester, New York, 14642, United States
Duke University
Durham, North Carolina, 27708, United States
University of Utah
Salt Lake City, Utah, 84112, United States
Murdoch Children's Research Institute
Melbourne, Australia
Study Completion
May 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 25, 2026
Record last verified: 2026-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: